Related Experiment Video

Updated: Feb 25, 2026

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

12.3K

Novel CD137 Gene Polymorphisms and Susceptibility to Ischemic Stroke in the Northern Chinese Han Population

Shuang Zhang1, Zongmin Li2, Ruyou Zhang3

  • 1Department of Ultrasound, The 2nd Affiliated Hospital of Harbin Medical University, NO.246, Xuefu Road, Nangang District, Harbin, 150081, Heilongjiang, People's Republic of China.

Neuromolecular Medicine
|July 30, 2017
PubMed

Insights

This study investigated CD137 gene single nucleotide polymorphisms (SNPs) and their link to ischemic stroke risk in a Chinese population. Specific CD137 SNPs were associated with increased ischemic stroke risk, particularly in patients with diabetes.

Area of Science:

  • Genetics
  • Neurology
  • Cardiovascular Disease

Background:

  • Ischemic stroke is a major global health concern, with atherosclerosis as a key risk factor.
  • Emerging research highlights the role of CD137 in human atherosclerosis.

Purpose of the Study:

  • To analyze the association between CD137 gene single nucleotide polymorphisms (SNPs) and ischemic stroke risk.
  • To investigate these associations in a northern Chinese Han population, considering subgroups with diabetes and hypertension.

Main Methods:

  • Genotyping of three CD137 SNPs (rs161827, rs161818, rs161810) in 496 ischemic stroke patients and 486 controls.
  • Utilizing multivariable logistic regression and permutation analysis to assess allele, genotype, and haplotype associations.
  • Stratifying analysis by diabetes, hypertension, and ischemic stroke subtypes.

Main Results:

  • Significant associations were found between rs161827 and ischemic stroke, particularly in patients with diabetes.
  • SNPs rs161818 and rs161810 showed significant differences in patients without diabetes compared to controls.
  • All three studied SNPs (rs161827, rs161818, rs161810) were statistically significant in the combination stroke subgroup.

Conclusions:

  • The CD137 gene is associated with ischemic stroke risk in the northern Han Chinese population.
  • CD137 gene polymorphisms may mediate the link between diabetes and ischemic stroke.

Keywords:
Association studiesCD137InflammationIschemic strokeSNPs

Related Concept Videos

Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
18.8K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
57
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
54
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
15.9K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
49
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
51